The OTX-TKI study is a phase 1 open-label, dose escalation study of OTX-TKI (axitinib implant) for intravitreal use in subjects with neovascular Age-related macular degeneration (AMD).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 21 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | 3:1 |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) |
| Actual Study Start Date : | July 28, 2021 |
| Estimated Primary Completion Date : | September 2022 |
| Estimated Study Completion Date : | December 2022 |
